Michael Walsh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1577247/publications.pdf

Version: 2024-02-01

159 papers 16,573 citations

54 h-index 125 g-index

164 all docs

164 docs citations

164 times ranked 15144 citing authors

#	Article	IF	CITATIONS
1	Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease. Quality of Life Research, 2022, 31, 567-577.	1.5	3
2	Improvement of kidney function in patients with chronic kidney disease and severe obesity after bariatric surgery: A systematic review and metaâ€analysis. Nephrology, 2022, 27, 44-56.	0.7	12
3	Impact of Bioelectrical Impedance–Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2022, 79, 820-831.	2.1	6
4	A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. Journal of Clinical Epidemiology, 2022, 142, 144-151.	2.4	8
5	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study. CKJ: Clinical Kidney Journal, 2022, 15, 681-692.	1.4	10
6	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney International Reports, 2022, 7, 200-209.	0.4	31
7	Plasma Exchange in ANCA-Associated Vasculitis: For Whom (If Any)?. Journal of the American Society of Nephrology: JASN, 2022, , ASN.2021121550.	3.0	0
8	Association of abnormal electrocardiograph metrics with prolonged recovery time in incident hemodialysis patients. BMC Nephrology, 2022, 23, 46.	0.8	0
9	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open, 2022, 12, e050507.	0.8	11
10	Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ, The, 2022, 376, e064597.	3.0	25
11	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ, The, 2022, 376, e064604.	3.0	42
12	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.4	3
13	Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey. Journal of Pain and Symptom Management, 2021, 61, 237-245.e2.	0.6	5
14	The WISHED Randomized Controlled Trial: Impact of an Interactive Health Communication Application on Home Dialysis Use in People With Chronic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110196.	0.6	0
15	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	3.0	322
16	Allopurinol: Good for Gout But Not for Preventing Loss of Kidney Function. American Journal of Kidney Diseases, 2021, 77, 459-461.	2.1	4
17	Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. PLoS ONE, 2021, 16, e0248567.	1.1	1
18	Prevalence of Frailty in Patients Referred to the Kidney Transplant Waitlist. Kidney360, 2021, 2, 1287-1295.	0.9	10

#	Article	IF	CITATIONS
19	Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis., 2021, 3, e0399.		23
20	Mineralocorticoid Receptor Antagonists in CKD: In Need of a Few Large Trials. American Journal of Kidney Diseases, 2021, 77, 813-815.	2.1	0
21	Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses. Journal of Clinical Epidemiology, 2021, 134, 95-102.	2.4	13
22	Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. Contemporary Clinical Trials, 2021, 107, 106466.	0.8	0
23	Burden of mental health symptoms and perceptions of their management in in-centre hemodialysis care: a mixed methods study. Journal of Patient-Reported Outcomes, 2021, 5, 111.	0.9	7
24	Variability in Cardiac Biomarkers during Hemodialysis: A Prospective Cohort Study. Clinical Chemistry, 2021, 67, 308-316.	1.5	3
25	Response to: â€~Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones <i>et al'</i> by Vandergheynst <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e101-e101.	0.5	0
26	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	2.6	260
27	The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 782-789.	0.4	16
28	Fragility of clinical trials across research fields: A synthesis of methodological reviews. Contemporary Clinical Trials, 2020, 97, 106151.	0.8	8
29	Implementing a Patient-Reported Outcome Measure for Hemodialysis Patients in Routine Clinical Care. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1299-1309.	2.2	29
30	Use of Critical Items in Determining Point-of-Care Ultrasound Competence. Evaluation and the Health Professions, 2020, 44, 016327872097583.	0.9	1
31	Preoperative <i>N</i> -Terminal Pro–B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery. Annals of Internal Medicine, 2020, 172, 96.	2.0	99
32	Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Cmaj, 2020, 192, E901-E906.	0.9	271
33	Frailty and the Kidney Transplant Wait List: Protocol for a Multicenter Prospective Study. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812095743.	0.6	6
34	A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol. BMC Health Services Research, 2020, 20, 731.	0.9	23
35	The Dialysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) Trial: A Protocol for a Randomized, Crossover, Placebo-Controlled Blinded Trial. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096895.	0.6	5
36	SONAR. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 889-891.	2.2	3

#	Article	IF	Citations
37	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	13.9	465
38	Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology, 2019, 58, 103-109.	0.9	24
39	Screening questions for the diagnosis of restless legs syndrome in hemodialysis. CKJ: Clinical Kidney Journal, 2019, 12, 559-563.	1.4	5
40	Association between complications and death within 30 days after noncardiac surgery. Cmaj, 2019, 191, E830-E837.	0.9	181
41	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	2.9	82
42	A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. Journal of Clinical Epidemiology, 2019, 113, 159-167.	2.4	19
43	Bioavailability of oral curcumin. Cmaj, 2019, 191, E428-E428.	0.9	7
44	Change in albuminuria as a surrogate endpoint in chronic kidney disease. Lancet Diabetes and Endocrinology, the, 2019, 7, 335.	5.5	2
45	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
46	Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 34-39.	1.0	2
47	Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial. Cmaj, 2019, 191, E247-E256.	0.9	19
48	Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811882194.	0.6	3
49	Single Questions for the Screening of Anxiety and Depression in Hemodialysis. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811882544.	0.6	13
50	The Fragility of Statistically Significant Randomized Controlled Trials in Plastic Surgery. Plastic and Reconstructive Surgery, 2019, 144, 1238-1245.	0.7	11
51	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811989439.	0.6	7
52	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases, 2019, 78, 399-405.	0.5	165
53	A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. Clinical Chemistry, 2019, 65, 427-436.	1.5	16
54	Long-term low-dose maintenance glucocorticoids in ANCA vasculitis. Clinical Nephrology, 2019, 91, 200-205.	0.4	0

#	Article	lF	Citations
55	Blood HER2 and Uromodulin as Causal Mediators of CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1326-1335.	3.0	21
56	Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811774953.	0.6	38
57	HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. American Journal of Kidney Diseases, 2018, 71, 166-172.	2.1	90
58	Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease-1: Study Protocol for a Multicenter Clinical Trial. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811881308.	0.6	12
59	Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial. Cmaj, 2018, 190, E1273-E1280.	0.9	27
60	Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model. Thrombosis Research, 2018, 172, 181-187.	0.8	15
61	External validation of the Revised Cardiac Risk Index and update of its renal variable to predict 30-day risk of major cardiac complications after non-cardiac surgery: rationale and plan for analyses of the VISION study. BMJ Open, 2017, 7, e013510.	0.8	30
62	P1_185 The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: a Systematic Review and Meta-Analysis. Rheumatology, 2017, 56, iii103-iii103.	0.9	2
63	Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA - Journal of the American Medical Association, 2017, 317, 1642.	3.8	579
64	The Fragility of Statistically Significant Findings From Randomized Trials in Sports Surgery: A Systematic Survey. American Journal of Sports Medicine, 2017, 45, 2164-2170.	1.9	128
65	Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 965-973.	2.2	25
66	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Research and Therapy, 2017, 19, 129.	1.6	42
67	When is a meta-analysis conclusive? A guide to Trial Sequential Analysis with an example of remote ischemic preconditioning for renoprotection in patients undergoing cardiac surgery. Nephrology Dialysis Transplantation, 2017, 32, ii23-ii30.	0.4	22
68	Risks and Benefits of Glucocorticoids in ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology, 2017, 3, 244-253.	0.6	3
69	Discrimination and Calibration of Clinical Prediction Models. JAMA - Journal of the American Medical Association, 2017, 318, 1377.	3.8	920
70	Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2633-2635.	1.2	3
71	Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil. BMC Cardiovascular Disorders, 2017, 17, 148.	0.7	2
72	The WISHED Trial: Implementation of an Interactive Health Communication Application for Patients with Chronic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2016, 3, 120.	0.6	4

#	Article	IF	Citations
73	Plasmapheresis for the treatment of kidneyÂdiseases. Kidney International, 2016, 90, 974-984.	2.6	43
74	Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ, The, 2016, 355, i5599.	3.0	25
75	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 591-598.	2.1	74
76	Effects of remote ischemic preconditioning in high-risk patients undergoing cardiac surgery (Remote) Tj ETQq0	0 O rgBT /0	Overlock 10 T
77	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. Journal of Rheumatology, 2016, 43, 97-120.	1.0	66
78	ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. PLoS ONE, 2016, 11, e0165402.	1.1	21
79	Establishing a Canadian National Clinical Trials Network for Kidney Disease: Proceedings of a Planning Workshop. Canadian Journal of Kidney Health and Disease, 2015, 2, 80.	0.6	4
80	Trace element supplementation in hemodialysis patients: a randomized controlled trial. BMC Nephrology, 2015, 16, 52.	0.8	35
81	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides – Executive Summary. Canadian Journal of Kidney Health and Disease, 2015, 2, 78.	0.6	12
82	Combined general and neuraxial anesthesia versus general anesthesia: a population-based cohort study. Canadian Journal of Anaesthesia, 2015, 62, 356-368.	0.7	23
83	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 2015, 74, 1178-1182.	0.5	217
84	The Safety of Eplerenone in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1602-1608.	2.2	50
85	Kidney Function Alters the Relationship between Postoperative Troponin T Level and Death. Journal of the American Society of Nephrology: JASN, 2015, 26, 2571-2577.	3.0	11
86	Clinician trialist rounds: 28. When RCT participants are lost to follow-up. Part 1: Why even a few can matter. Clinical Trials, 2015, 12, 537-539.	0.7	22
87	The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine Journal, 2015, 15, 2188-2197.	0.6	157
88	The Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis (SIMPL) Pilot Trial. Canadian Journal of Kidney Health and Disease, 2014, 1, 30.	0.6	24
89	Economic Evaluation of Frequent Home Nocturnal Hemodialysis Based on a Randomized Controlled Trial. Journal of the American Society of Nephrology: JASN, 2014, 25, 587-594.	3.0	54
90	Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial. BMJ Open, 2014, 4, e004842.	0.8	10

#	Article	IF	CITATIONS
91	Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. BMJ Open, 2014, 4, e004886.	0.8	10
92	Nonleg Venous Thrombosis in Critically Ill Adults. JAMA Internal Medicine, 2014, 174, 689.	2.6	43
93	Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease. CKJ: Clinical Kidney Journal, 2014, 7, 562-568.	1.4	7
94	Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2014, 311, 2191.	3.8	167
95	Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury. JAMA - Journal of the American Medical Association, 2014, 312, 2254.	3.8	105
96	Plasma exchange in antineutrophil cytoplasm antibody-associated vasculitis. Current Opinion in Nephrology and Hypertension, 2014, 23, 555-559.	1.0	8
97	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults. American Journal of Kidney Diseases, 2014, 63, 363-377.	2.1	28
98	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in Children. American Journal of Kidney Diseases, 2014, 63, 354-362.	2.1	42
99	Establishing a National Knowledge Translation and Generation Network in Kidney Disease: The CAnadian KidNey KNowledge TraNslation and GEneration NeTwork. Canadian Journal of Kidney Health and Disease, 2014, 1, 2.	0.6	10
100	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1571-1576.	2.2	53
101	The impact of patient preference on dialysis modality and hemodialysis vascular access. BMC Nephrology, 2014, 15, 38.	0.8	17
102	Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. BMC Nephrology, 2014, 15, 53.	0.8	38
103	The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. Journal of Clinical Epidemiology, 2014, 67, 622-628.	2.4	504
104	A Modification of the Pulmonary Autograft Procedure to Prevent Late Autograft Dilatation. Pediatric Cardiac Surgery Annual, 2014, 17, 38-42.	0.5	3
105	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	1.3	740
106	In Reply. Anesthesiology, 2014, 120, 1280-1281.	1.3	0
107	Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials, 2013, 14, 73.	0.7	198
108	Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 219-224.	2.2	49

#	Article	IF	Citations
109	Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study. American Journal of Kidney Diseases, 2013, 61, 710-715.	2.1	56
110	Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney International, 2013, 84, 397-402.	2.6	220
111	Association of Calcium, Phosphate and Parathyroid Hormone with Renal Allograft Function: A Retrospective Cohort Study. American Journal of Nephrology, 2013, 37, 339-345.	1.4	9
112	The Risk of Perioperative Bleeding in Patients With Chronic Kidney Disease. Annals of Surgery, 2013, 258, 901-913.	2.1	58
113	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	3.0	6
114	The Association Between Perioperative Hemoglobin and Acute Kidney Injury in Patients Having Noncardiac Surgery. Anesthesia and Analgesia, 2013, 117, 924-931.	1.1	88
115	Relationship between Intraoperative Mean Arterial Pressure and Clinical Outcomes after Noncardiac Surgery. Anesthesiology, 2013, 119, 507-515.	1.3	1,107
116	Timing of initiation of renal replacement therapy for acute kidney injury: a survey of nephrologists and intensivists in Canada. Nephrology Dialysis Transplantation, 2012, 27, 2761-2767.	0.4	45
117	Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 2295.	3.8	821
118	Tubular Lesions Predict Renal Outcome in Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis after Rituximab Therapy. Journal of the American Society of Nephrology: JASN, 2012, 23, 313-321.	3.0	109
119	Peritoneal Dialysis Patients with Critical Illness: Insurance May be Hard to Come By. Peritoneal Dialysis International, 2012, 32, 7-9.	1.1	0
120	Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial. BMJ Open, 2012, 2, e001080.	0.8	12
121	Secular trends in acute dialysis after elective major surgery — 1995 to 2009. Cmaj, 2012, 184, 1237-1245.	0.9	111
122	Regional Anesthesia Improves Outcome After Distal Radius Fracture Fixation Over General Anesthesia. Journal of Orthopaedic Trauma, 2012, 26, 545-549.	0.7	61
123	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.5	348
124	Evolution of Heterogeneity (I2) Estimates and Their 95% Confidence Intervals in Large Meta-Analyses. PLoS ONE, 2012, 7, e39471.	1.1	192
125	Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injuryâ€"A prospective multicenter observational study. Journal of Critical Care, 2012, 27, 268-275.	1.0	67
126	Assessment of healthâ€related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2012, 64, 273-279.	1.5	49

#	Article	IF	Citations
127	Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis and Rheumatism, 2012, 64, 542-548.	6.7	298
128	Assessment and Implication of Prognostic Imbalance in Randomized Controlled Trials with a Binary Outcome – A Simulation Study. PLoS ONE, 2012, 7, e36677.	1.1	23
129	The Effect of Nocturnal and Conventional Hemodialysis on Markers of Nutritional Status: Results From a Randomized Trial., 2011, 21, 271-276.		26
130	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.5	719
131	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. American Journal of Kidney Diseases, 2011, 57, 566-574.	2.1	179
132	Long-term damage to the ENT system in Wegener's granulomatosis. European Archives of Oto-Rhino-Laryngology, 2011, 268, 733-739.	0.8	17
133	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	1.5	63
134	High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: A prospective cohort study. Clinical Biochemistry, 2011, 44, 1021-1024.	0.8	84
135	Preventing Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis—Reply. JAMA - Journal of the American Medical Association, 2011, 305, 996.	3.8	1
136	Statin Use Associates with a Lower Incidence of Acute Kidney Injury after Major Elective Surgery. Journal of the American Society of Nephrology: JASN, 2011, 22, 939-946.	3.0	105
137	The Number of Patients and Events Required to Limit the Risk of Overestimation of Intervention Effects in Meta-Analysisâ€"A Simulation Study. PLoS ONE, 2011, 6, e25491.	1.1	281
138	Effects of Perioperative Blood Product Use on Surgical Site Infection Following Thoracic and Lumbar Spinal Surgery. Spine, 2010, 35, 340-346.	1.0	78
139	Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2010, 55, 1026-1039.	2.1	177
140	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A metaâ€analysis. Arthritis Care and Research, 2010, 62, 1166-1173.	1.5	200
141	Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis. BMC Nephrology, 2010, 11, 13.	0.8	10
142	The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomizedâ€controlled trial. Hemodialysis International, 2010, 14, 174-181.	0.4	57
143	Histopathologic Features Aid in Predicting Risk for Progression of IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 425-430.	2.2	79
144	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	3.8	524

#	Article	IF	CITATIONS
145	Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus, 2010, 19, 628-633.	0.8	29
146	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	13.9	1,471
147	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	1.0	35
148	Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney International, 2009, 75, 542-549.	2.6	73
149	Ascorbic Acid for Anemia Management in Hemodialysis Patients: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2009, 54, 1089-1097.	2.1	57
150	Targeting the B cell in vasculitis. Pediatric Nephrology, 2009, 24, 1267-1275.	0.9	15
151	What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?. Current Opinion in Rheumatology, 2009, 21, 256-261.	2.0	12
152	Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney International, 2007, 72, 676-682.	2.6	54
153	Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 993-999.	3.0	154
154	Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. JAMA - Journal of the American Medical Association, 2007, 298, 1291.	3.8	603
155	Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 968-975.	2.2	119
156	Identification of a novel protein kinase A phosphorylation site, S449, on the delayed rectifier potassium channel, Kv1.2. FASEB Journal, 2007, 21, A1242.	0.2	0
157	Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. Journal of Nephrology, 2007, 20, 119-29.	0.9	3
158	The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study. BMC Nephrology, 2006, 7, 2.	0.8	21
159	A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney International, 2005, 67, 1500-1508.	2.6	179